Mutational inactivation of the retinoblastoma gene (RB) is found in all retinoblastomas and in a subset of other human neoplasms, including sarcomas of bone or soft tissue and carcinomas of lung or breast. Exogenous copies of wild-type RB have been shown to suppress the tumorigenicity of several types of tumor cells with endogenous RB mutations, including a previously described human prostatic carcinoma cell line. To further support a role for RB inactivation in the genesis ofprostate cancer, seven primary or metastatic prostate carcinoma specimens were examined for evidence of RB mutation. By the use of immunoblot analysis and immunostaining of histologic sections, RB-encoded protein was readily detected in tumor cells offive specimens, was equivocally detected in one specimen, and was apparently absent from tumor cells of one specimen. RB mutations in the latter case were precisely characterized as (I) a deletion of 103 nucleotides containing transcriptional start sites and (it) loss of the second RB allele.
wild-type RB have been shown to suppress the tumorigenicity of several types of tumor cells with endogenous RB mutations, including a previously described human prostatic carcinoma cell line. To further support a role for RB inactivation in the genesis ofprostate cancer, seven primary or metastatic prostate carcinoma specimens were examined for evidence of RB mutation. By the use of immunoblot analysis and immunostaining of histologic sections, RB-encoded protein was readily detected in tumor cells offive specimens, was equivocally detected in one specimen, and was apparently absent from tumor cells of one specimen. RB mutations in the latter case were precisely characterized as (I) a deletion of 103 nucleotides containing transcriptional start sites and (it) loss of the second RB allele.
The 103-base-pair deletion was sufficient to abolish the promoter activity of upstream DNA sequences in a heterologous expression system. These results (i) demonstrate thatRB can be inactivated in vivo by mutation of its promoter, (ii) confirm the existence ofRB mutations in some human prostate carcinomas, and (iii) suggest the use of immunohistochemical methods to screen for RB mutations in clinical samples of common adult neoplasms. mutations, as predicted by Knudson (9) . RB mutations are also found in a subset of osteosarcomas, soft-tissue sarcomas, and carcinomas of breast and lung, suggesting a broad role for RB inactivation in the genesis of human tumors (8) .
Finally, restoration of the normal RB gene product, ppllORB, into pp11ORB-deficient (RB-) tumor cells alters several aspects of their neoplastic phenotype, including suppression of tumorigenicity in nude mice (10, 11) . Because of these properties, RB is a model for studying other candidate tumor suppressor genes.
In a previous study of three human prostate carcinoma cell lines, one was found to express a mutated RB mRNA and an abnormally small RB protein that was functionally inactive in tumor suppression (11) . To establish the existence of RB mutations in native prostate carcinomas, primary or metastatic tumor specimens were screened for loss of RB protein expression. Two tumors were found to have severely reduced or undetectable amounts of RB protein by immunoblot analysis and by immunostaining of histologic sections. Direct detection of mutated RB alleles is hindered by the large size (';200 kilobases) and structural complexity (27 exons) of this gene (12) . Nevertheless, a detailed genetic analysis of one tumor revealed both mutations leading to RB inactivation: (i) a 103-base-pair (bp) deletion that abolished activity of the RB promoter and (ii) loss of the second normal RB allele. Prostate carcinoma is the most common cancer in men (1). Despite its high incidence, the genetic alterations affecting prostate cancer cells are poorly understood. Genetic analyses of common adult neoplasms, as well as of several unusual childhood tumors, have suggested that the cancer phenotype is broadly determined by two classes ofgenes, oncogenes and tumor suppressor genes, that are functionally opposed (2) . ras and myc oncogenes, activated by mutation or overexpression, have an uncertain role in the genesis of prostatic neoplasms (3) (4) (5) , although a mouse model for multistage carcinogenesis was created by introducing these oncogenes into prostatic precursor cells (6) . Deletion of chromosome region 10q24 has been identified in several prostate carcinomas; karyotypes of these tumors are otherwise intractably complex (7) . Loss of heterozygosity of specific genetic markers, suggestive ofthe inactivation ofnearby tumor suppressor genes, has not been reported in prostate cancer.
Of the few tumor suppressor genes cloned to date, the retinoblastoma gene (RB) is certainly prototypic. Both alleles ofthis gene are invariably mutated in retinoblastoma, a tumor of childhood that arises in the immature retina (8) . In hereditary retinoblastoma, one mutation is inherited in the germ line, whereas nonhereditary tumors require two somatic MATERIALS AND METHODS Origin of Prostate Carcinoma Specimens. Unfixed tumor samples and benign prostate tissue were collected in conjunction with surgical procedures or autopsies, and were stored at -70'C until used. Tumor 7 was obtained from a patient (patient 4) whose neoplasm was included in a previous study of neuroendocrine differentiation in prostatic carcinomas (13) .
Immunoblot Analysis. Frozen samples were pulverized in mortars on dry ice and lysed in 1 ml of ice-cold lysis buffer (50 mM Hepes, pH 7.5/150 mM NaCI/0.1% Nonidet P-40/50 mM NaF/1 mM phenylmethylsulfonyl fluoride). After clarification (20,000 x g for 5 min), lysates were equalized for total protein content (MicroBCA kit, Pierce) and supplemented with protease inhibitors aprotinin (Boehringer Mannheim) and leupeptin (Sigma) at 10 tuM and 50 uM, respectively. Lysates were immunoprecipitated with rabbit polyclonal anti-fRB IgG (1.5 ;kg/ml) (14) , anti-esterase D IgG (1.0 pug/ml) (15) , or anti-c-Abl IgG (1.0 ,ug/ml) (16) In brief, 10-pAm-thick cryosections of frozen tumor fragments were immediately fixed in ice-cold acetone for 10 min and then air-dried. Slides were washed for 10 min in PBS (10 mM sodium phosphate/0.15 M NaCl, pH 7.2), blocked for 30 min in 3% (vol/vol) normal goat serum in PBS (NGS/PBS), and then incubated overnight in NGS/PBS with or without affinity-purified rabbit polyclonal anti-RBO.47 IgG (0.5 pug/ml) (22) . Washing and blocking steps were repeated, and slides were incubated for 1 hr with biotinylated goat anti-rabbit IgG (Vector Laboratories) diluted 1:200 in NGS/PBS. Slides were washed, incubated for 45 min in ABC reagent (Vector Laboratories), washed again, and then developed in 0.02% 3,3'-diaminobenzidine tetrahydrochloride (Sigma)/0.01% H202/PBS. Nuclear counterstaining, if required, was done with 0.25% aqueous methyl green (Sigma), followed by dehydration and permanent mounting.
DNA Extraction. Frozen tumor fragments were serially cryosectioned at 10-pum intervals. The first and last sections were examined by routine histology. Genomic DNA was extracted from the intervening sections (-0.02 cm3 of total tissue) by standard procedures (23) .
Genomic Polymerase Chain Reaction (PCR). RB promoter DNA fragments were amplified by mixing primers RbPro-1 (500 ng; 5'-TGCACTAGCCAGATATTCCCTGC-3') and Rb-4 (500 ng; 5'-TCCCGACTCCCGTTACAA-3'), 1 pug of genomic DNA, 10 p.l of dimethyl sulfoxide, and 1 unit of Thermus aquaticus polymerase (Cetus) with PCR buffer (50 mM KCl/10 mM Tris HCl, pH 8. Mixtures were processed through 33 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min, followed by a single 5-min extension step in a programmable heat block (Ericomp, San Diego, CA). The highly polymorphic region in intron 20 of the RB gene (24) was amplified by mixing primers Rb-35 (250 ng; 5'-GAACGCCTTCTGTCTGAG-3') and VNTR20 (250 ng; 5'-AATTAACAAGGTGTGGTGG-3'), 1 pug of genomic DNA, 10 p.l of dimethyl sulfoxide, and 1 unit of Thermus aquaticus polymerase with PCR buffer and dNTPs in 100 jul. An additional 10-50 ng of Rb-35 radiolabeled with [y_3 P]ATP and T4 kinase (25) was included as a tracer. Reaction conditions were 28 cycles of denaturation at 94°C for 30 sec, annealing at 52°C for 30 sec, and extension at 72°C for 30 sec, followed by a single 5-min extension step. The resulting allele sizes were approximately 400 base pairs (bp). PCR products (5 p.l) were denatured by boiling with equal volumes of 0.37% EDTA sequencing stop buffer and loaded on a 6% polyacrylamide sequencing gel as described (24) .
Direct Sequencing. PCR-amplified DNA was purified on 8% polyacrylamide gels and Elutip-d columns (Schleicher & Schuell). Primers Rb-4 (see above) and PR-1 (5'-TCTGGG-TAGAAGCACGTCCGG-3') were radiolabeled with [_32p]_ ATP and T4 kinase and purified by spin-column chromatography (25) with Bio-Gel P-30 (Bio-Rad). Sequencing reactions were performed with reagents supplied in a T7 polymerase sequencing kit (Pharmacia LKB). Approximately 200 ng of template DNA was mixed with 12 ng of primer and 1 p.l of dimethyl sulfoxide in 15 p.l and denatured at 95TC for 3 min. After quickly chilling this mixture on ice, 2 of annealing buffer was added, and the mixture was annealed at 370C for 20 min and then at room temperature for 10 min. Instead of labeling reagents, 1 A.l of 4 p.M dATP and 2 p.l of diluted T7 polymerase (1.5 units/pLI) were added. The mixture was immediately distributed into four termination reaction tubes (4.5 ILI per tube), and the procedure was continued according to kit instructions. Reaction products were separated on a 6% polyacrylamide sequencing gel, and the gel was autoradiographed.
RB Promoter-Driven Chloramphenicol Acetyltransferase (CAT) Expression Assay. Tumor 7 DNA was amplified with linker-containing primers, and the aberrant promoter fragment ASH was digested with HindIII and Sst I and gel-purified as described above. Plasmid pRbCAT2, containing the normal RB promoter driving the bacterial CAT gene (12) , was linearized with Sst I and partially digested with HindIII. A 4.4-kilobase fragment (pRbCAT2 minus the RB promoter) was purified from agarose gels and ligated to ASH, resulting in PASHCAT. CV-1 cells were transfected with PASHCAT DNA and other previously characterized control plasmids as described (12) ; promoter inserts in all plasmids had similar 3' termini but varied at their 5' ends. Assays for transient expression of CAT and luciferase (an internal control for transfection efficiency) were performed as described by Hong et al. (12) .
RESULTS

RB Protein Expression in Human Prostate
Carcinomas. RB mRNA is expressed constitutively in most nonneoplastic tissues (26, 27) and encodes a nuclear phosphoprotein of apparent Mr 110,000-116,000, depending on the extent of phosphorylation (28) . Loss of RB protein expression, or expression of shortened RB polypeptides, as determined by immunoblot analysis, has proved to be a sensitive indicator of RB mutation in several types of cultured tumor cells (11, 14, 17, (28) (29) (30) , and similar methods might be applied to native tumor specimens. To minimize the problem of contaminating nonneoplastic elements, which could obscure the lack of RB protein in tumor cells, metastatic or bulky prostate tumors were favored for initial examination (Table 1) . Approximately equal quantities of normal-sized RB protein were detected in benign prostate tissue (data not shown) and in three tumor samples, whereas RB protein content was significantly reduced in one specimen and was undetectable in lysates of two others (Table 1) . To confirm the specific loss of RB protein from tumor cells, immunohistochemical meth- ods were developed to detect RB protein in histologic sections (Fig. 1) . Distinct nuclear staining was observed in benign prostatic epithelial cells (Fig. la) and in tumor cells of several prostate carcinomas (Table 1) . Nearly all nuclei were stained in tumors 1 and 4 ( Fig. 1 b and and 4) , and from tumors 3 and 4 (lanes 5 and 6, respectively) was amplified in vitro with two oligonucleotide primers flanking the RB promoter. PCR products were separated on an 8% polyacrylamide gel and visualized by ethidium bromide staining. Lane 1 was a no-template control. Aberrant shortened fragments were apparent only in DNA from tumor 7; exact fragment sizes (right) were inferred from results presented in Fig. 3 . Lane M contains the size markers. size (422 bp). However, PCR products with template DNA from two portions of tumor 7 contained two distinct bands, one normal-sized and the other about 100 bp smaller ( Fig. 2A,  lanes 3 and 4) . As assessed by histologic sections, one template DNA sample (lane 3) was derived from a region of confluent tumor cells and minimal stroma, whereas the other (lane 4) was derived from mostly nonneoplastic tissue containing just a small nest of tumor cells. Correlatively, the quantity ratios of normal-sized and small amplified fragments .; small PCR fragment suggested a deletion of about 100 bp between the two amplification primers in template DNA; its variable relative quantity in the two template samples further suggested that the small fragment was specific to tumor cell DNA and not to somatic DNA. We suspected that tumor cells were homozygous rather than heterozygous for the putative promoter deletion because, in one portion of the specimen, the quantity of the deletion fragment vastly exceeded that of the normal fragment. If so, the other, normal RB allele must have been lost during tumorigenesis. To support this hypothesis, tumor 7 DNA was tested for loss of heterozygosity of genetic polymorphisms within RB. A polymorphism in intron 20 (24) was particularly useful for this purpose because it consisted of a variable number of short (4-5 bp) tandemly repeated sequences that could be amplified by PCR (Fig. 2B) . Heterozygosity for this variable number of tandem repeats (VNTR) polymorphism was clearly demonstrated in the DNA sample derived from mostly nonneoplastic cells (Fig. 2B, left lane) . However, the sample with predominance of tumor DNA showed a marked reduction in intensity of the smaller VNTR allele relative to the larger one (Fig. 2B, right lane) . These results strongly suggested that one of the two RB alleles present in somatic cells from this patient was lost from tumor cells, leaving only the mutated RB allele.
Deletion within the RB promoter region was confirmed by directly sequencing the smaller DNA fragment amplified by promoter primers from tumor 7 DNA. Alignment with the normal promoter sequence (12) showed a simple deletion of nucleotides 29-131 (103 bp) (Fig. 3) . This deletion removed putative transcriptional start sites at nucleotides 44 and 51, and most of a region, nucleotides 13-83, shown to be necessary for RB promoter activity (12) . The translational start codon at nucleotide 277 was not involved in this mutation. Therefore, it was plausible that this deletion might inactivate RB by severely decreasing or eliminating the transcription of RB mRNA in tumor cells.
Internal Deletion Abrogated RB Promoter Activity. The post-mortem origin of tumor 7 precluded direct Northern blot analysis of RB mRNA. Therefore, its promoter deletion was functionally analyzed in a CAT expression system. The amplified deletion fragment (319 bp not counting linkers) was ligated upstream of the CAT gene in a construct analogous to those with normal RB promoter fragments (12) . Transfection of CV-1 cells with DNA from several independent clones of this plasmid resulted in CAT activities at about the same level as that of a promoterless CAT construct (Fig. 4) ; normal RB promoter-containing constructs yielded CAT activities >10-fold higher than basal activity, as shown (12) . These RB Inactivation by a Deletion Within Its Promoter. RB expression in one prostate tumor was ablated by two mutations: a 103-bp deletion within the promoter region of one RB allele, and loss ofthe second (normal) RB allele. These results support a study (12) localizing essential promoter elements to bp 13-83. Because bp 13-28 are evidently insufficient to confer promoter activity, the essential region may be further restricted to bp 29-83. The frequency of promoter mutation as a basis for RB inactivation is unknown. Several independent 8-thalassemia mutations consist of base substitutions in highly conserved promoter sequences, but transcription of the f3-globin gene is reduced rather than eliminated entirely (33) . If reduced expression of RB is still sufficient for normal function, then deletion will be the principal promoter mutation observed in tumor cells. PCR amplification and sequencing ofthe RB promoter region have been hampered by its high content of C+G nucleotides (12) ; both procedures were found to be facilitated by the addition of dimethyl sulfoxide to reaction mixes (34) . Analysis of other natural promoter mutations may further specify critical promoter sequences within bp 29-83.
Thus with our previous study of three prostate carcinoma cell lines (11) , RB mutations have been characterized in 2 of 10 independent prostate cancers. The prevalence of RB mutations in these tumors may be preliminarily estimated at 10- 
